Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313079 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Steven E. Coutre.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00313079 is a Phase 1 study that has completed, run by Steven E. Coutre. The registered enrollment target is 9 participants.
The verdict
NCT00313079, a Phase 1 study, has completed, sponsored by Steven E. Coutre.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.
Interventions
- DRUG Vincristine
- DRUG MAb 216
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313079
The ClinicalTrials.gov registry entry for NCT00313079 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steven E. Coutre, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vincristine is the first listed.
NCT00313079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313079 about?
NCT00313079 is a clinical study titled "Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia". A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.
What is the current status of trial NCT00313079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00313079?
The interventions under investigation include: Vincristine (DRUG), MAb 216 (DRUG).
Who is sponsoring clinical trial NCT00313079?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.